[{"AccountsPayableCurrent_0_Q2_USD":383900000.0,"PaymentsOfFinancingCosts_2_Q2_USD":24400000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":10400000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-8500000.0,"AccruedIncomeTaxesNoncurrent_0_Q2_USD":743200000.0,"AccruedRoyaltiesCurrent_0_Q2_USD":203000000.0,"AllocatedShareBasedCompensationExpenseNetOfTax_1_Q2_USD":45500000.0,"AllocatedShareBasedCompensationExpenseNetOfTax_2_Q2_USD":121900000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":7300000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":900000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":2859100000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":2865500000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":1942700000.0,"RealizedInvestmentGainsLosses_2_Q2_USD":29500000.0,"BusinessCombinationContingentConsiderationLiabilityCurrent_0_Q2_USD":149100000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":-532700000.0,"ConstructionPayableCurrentAndNoncurrent_0_Q2_USD":24100000.0,"DebtInstrumentFairValue_0_Q2_USD":8257600000.0,"DebtSecuritiesAvailableForSaleRealizedGain_1_Q2_USD":6100000.0,"DebtSecuritiesAvailableForSaleRealizedGain_2_Q2_USD":11800000.0,"DebtSecuritiesAvailableForSaleRealizedLoss_1_Q2_USD":5200000.0,"DebtSecuritiesAvailableForSaleRealizedLoss_2_Q2_USD":24300000.0,"DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_1_Q2_USD":0.0,"DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_2_Q2_USD":0.0,"EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1_Q2_pure":0.0,"EffectiveIncomeTaxRateReconciliationDispositionOfAssets_2_Q2_pure":0.0,"EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_1_Q2_pure":0.002,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q2_USD":202500000.0,"RealizedInvestmentGainsLosses_1_Q2_USD":106800000.0,"ImpairmentOfIntangibleAssetsExcludingGoodwill_1_Q2_USD":0.0,"ImpairmentOfIntangibleAssetsExcludingGoodwill_2_Q2_USD":0.0,"AvailableForSaleSecurities_0_Q2_USD":2865500000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":1575900000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":2955000000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":15100000.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":400000.0,"OtherAssetsCurrent_0_Q2_USD":638800000.0,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0_Q2_USD":862600000.0,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0_Q2_USD":858500000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0_Q2_USD":1942700000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q2_USD":1940800000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q2_USD":922800000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":2384900000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":16900000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-47000000.0,"OtherLiabilitiesCurrent_0_Q2_USD":2486500000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":3383800000.0,"PaymentsForProceedsFromOtherInvestingActivities_2_Q2_USD":0.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":-118800000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":-49500000.0,"StockholdersEquityOther_1_Q2_USD":0.0,"StockholdersEquityOther_2_Q2_USD":700000.0,"EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1_Q2_pure":-0.034,"EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_Q2_pure":-0.037,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":212000000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":1475400000.0,"PaymentsToAcquireOtherProductiveAssets_2_Q2_USD":0.0,"ProceedsFromPaymentsForOtherFinancingActivities_2_Q2_USD":19000000.0,"EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2_Q2_pure":0.002,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_Q2_shares":300000.0,"EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_1_Q2_pure":0.027,"EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1_Q2_pure":0.001,"OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2_Q2_USD":-3300000.0,"OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_1_Q2_USD":-51200000.0,"OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2_Q2_USD":-17400000.0,"OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1_Q2_USD":-100000.0,"OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2_Q2_USD":-900000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-85300000.0,"PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_2_Q2_USD":-3300000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":19200000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":3753900000.0,"PaymentsToAcquireBusinessesNetOfCashAcquired_2_Q2_USD":0.0,"PaymentsToAcquireInProcessResearchAndDevelopment_2_Q2_USD":75000000.0,"PaymentsToAcquireInterestInSubsidiariesAndAffiliates_2_Q2_USD":141800000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":900000.0,"PaymentsToMinorityShareholders_2_Q2_USD":0.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":3879900000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1_Q2_USD":1490600000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_2_Q2_USD":500000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2_Q2_USD":-42500000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":647600000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":1123900000.0,"ResearchAndDevelopmentInProcess_1_Q2_USD":0.0,"ResearchAndDevelopmentInProcess_2_Q2_USD":75000000.0,"RestructuringCharges_1_Q2_USD":0.0,"RestructuringCharges_2_Q2_USD":0.0,"TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_2_Q2_USD":635000000.0,"TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_1_Q2_USD":-6200000.0,"ProceedsFromHedgeInvestingActivities_2_Q2_USD":-7800000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":8700000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":436200000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":414800000.0,"EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2_Q2_pure":0.001,"EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_1_Q2_USD":1500000.0,"EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2_Q2_USD":3000000.0,"EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1_Q2_USD":7000000.0,"EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2_Q2_USD":20300000.0,"EquitySecuritiesFvNiGainLoss_1_Q2_USD":102900000.0,"EquitySecuritiesFvNiGainLoss_2_Q2_USD":42000000.0,"EquitySecuritiesFvNiRealizedGainLoss_1_Q2_USD":0.0,"EquitySecuritiesFvNiRealizedGainLoss_2_Q2_USD":0.0,"EquitySecuritiesFvNiUnrealizedGainLoss_1_Q2_USD":102900000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_2_Q2_USD":42000000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1_Q2_USD":-10000000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2_Q2_USD":-5500000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0_Q2_USD":220000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":126000000.0,"GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_1_Q2_USD":8300000.0,"GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_2_Q2_USD":5900000.0,"GoodwillImpairedAccumulatedImpairmentLoss_0_Q2_USD":0.0,"GoodwillOtherIncreaseDecrease_2_Q2_USD":-6800000.0,"IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_2_Q2_USD":0.0,"IncreaseDecreaseInAccruedIncomeTaxesPayable_2_Q2_USD":504600000.0,"IncreaseDecreaseInEquitySecuritiesFvNi_2_Q2_USD":39700000.0,"IncreaseDecreaseInOtherOperatingCapitalNet_2_Q2_USD":-9900000.0,"IntangibleAssetsGrossExcludingGoodwill_0_Q2_USD":8398200000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":244700000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":509100000.0,"NumberOfReportableSegments_2_Q2_segment":1.0,"EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_2_Q2_pure":0.015,"TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_2_Q2_USD":16800000.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_1_Q2_shares":300000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":198900000.0,"Revenues_1_Q2_USD":3681600000.0,"Revenues_2_Q2_USD":7215900000.0,"StockholdersEquity_0_Q2_USD":11308700000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0005,"EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1_Q2_pure":0.21,"EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_Q2_pure":0.21,"EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1_Q2_pure":0.004,"EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_Q2_pure":0.005,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":5014400000.0,"InterestExpense_1_Q2_USD":66000000.0,"InterestExpense_2_Q2_USD":110300000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":14466700000.0,"NotesPayableCurrent_0_Q2_USD":0.0,"OperatingIncomeLoss_2_Q2_USD":3794300000.0,"PaymentsForRepurchaseOfCommonStock_2_Q2_USD":5029100000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"PreferredStockValue_0_Q2_USD":0.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":555100000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":1125200000.0,"ShareBasedCompensation_2_Q2_USD":115800000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":-300000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":-48000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":160900000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":167000000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":1687000000.0,"OperatingIncomeLoss_1_Q2_USD":1974500000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3330700000.0,"ProfitLoss_1_Q2_USD":1606500000.0,"ProfitLoss_2_Q2_USD":2999000000.0,"AccountsReceivableNetCurrent_0_Q2_USD":2133600000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-181000000.0,"AdditionalPaidInCapital_0_Q2_USD":0.0,"AssetImpairmentCharges_1_Q2_USD":0.0,"AssetImpairmentCharges_2_Q2_USD":0.0,"Assets_0_Q2_USD":25511800000.0,"AssetsCurrent_0_Q2_USD":8493800000.0,"CommonStockValue_0_Q2_USD":100000.0,"CostsAndExpenses_1_Q2_USD":1707100000.0,"CostsAndExpenses_2_Q2_USD":3421600000.0,"Depreciation_1_Q2_USD":51300000.0,"Depreciation_2_Q2_USD":99700000.0,"EffectOfExchangeRateOnCashAndCashEquivalents_2_Q2_USD":3900000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":446100000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":738200000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":268800000.0,"IncreaseDecreaseInDueFromRelatedParties_2_Q2_USD":-149100000.0,"InventoryNet_0_Q2_USD":952700000.0,"Liabilities_0_Q2_USD":14222600000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":25511800000.0,"LiabilitiesCurrent_0_Q2_USD":3447100000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-3558700000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-389800000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":3415800000.0,"NetIncomeLoss_1_Q2_USD":1542100000.0,"NetIncomeLoss_2_Q2_USD":2941200000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":254700000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":61500000.0,"TreasuryStockValue_0_Q2_USD":2977100000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":133000000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":0.219,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":774100000.0,"PaymentsToAcquireIntangibleAssets_2_Q2_USD":37000000.0,"CashEquivalentsAtCarryingValue_0_Q2_USD":1869600000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":1510400000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":2895400000.0,"NotesPayable_0_Q2_USD":7423800000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q2_USD":-65500000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2_Q2_USD":-59600000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-44000000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-30600000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-31700000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":-45800000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-441400000.0,"TaxesPayableCurrent_0_Q2_USD":576700000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_Q2_USD":3736800000.0,"DeferredIncomeTaxAssetsNet_0_Q2_USD":1710200000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":180200000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":232800000.0,"EffectiveIncomeTaxRateReconciliationTaxCredits_1_Q2_pure":0.01,"EffectiveIncomeTaxRateReconciliationTaxCredits_2_Q2_pure":0.01,"InvestmentIncomeInterest_1_Q2_USD":7600000.0,"InvestmentIncomeInterest_2_Q2_USD":32000000.0,"ProceedsFromIssuanceOfLongTermDebt_2_Q2_USD":2967300000.0,"RepaymentsOfLongTermDebt_2_Q2_USD":1500000000.0,"EarningsPerShareDiluted_1_Q2_USD":9.59,"EarningsPerShareDiluted_2_Q2_USD":17.61,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q2_USD":2037500000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":166700000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":160600000.0,"StockIssuedDuringPeriodValueTreasuryStockReissued_2_Q2_USD":29100000.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.198,"EffectiveIncomeTaxRateReconciliationOtherAdjustments_1_Q2_pure":0.004,"EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_Q2_pure":0.001,"IncreaseDecreaseInInventories_2_Q2_USD":188200000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1_Q2_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2_Q2_USD":0.0,"GainLossOnDerivativeInstrumentsNetPretax_2_Q2_USD":3300000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":4200000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-200000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":11289200000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":411100000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":865500000.0,"EarningsPerShareBasic_1_Q2_USD":9.6,"EarningsPerShareBasic_2_Q2_USD":17.65,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0_Q2_USD":220000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0_Q2_USD":230000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0_Q2_USD":230000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q2_USD":220000000.0,"Goodwill_0_Q2_USD":5751000000.0,"LongTermDebt_0_Q2_USD":7423800000.0,"MinorityInterest_0_Q2_USD":-19500000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":64400000.0,"NetIncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":57800000.0,"NonoperatingIncomeExpense_1_Q2_USD":63000000.0,"NonoperatingIncomeExpense_2_Q2_USD":-57500000.0,"OtherAssetsNoncurrent_0_Q2_USD":1483300000.0,"StockIssuedDuringPeriodValueTreasuryStockReissued_1_Q2_USD":11100000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":1461500000.0,"ValuationAllowancesAndReservesBalance_0_Q2_USD":1174700000.0,"Ticker":"BIIB","CIK":"875045","name":"BIOGEN INC.","OfficialName":"Biogen Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"32775642095.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"SP500","filed":"20200722"}]